|
業務類別
|
Biotechnology |
|
業務概覽
|
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation. |
| 公司地址
| 822 A1A North, Suite 306, Ponte Vedra, FL, USA, 32082 |
| 電話號碼
| +1 904 300-0701 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.cadrenal.com |
| 員工數量
| 4 |
| Mr. Matthew K. Szot |
Chief Financial Officer and Principal Accounting Officer |
美元 435.85K |
31/07/2025 |
| Dr. James J. Ferguson, III,M.D. |
Chief Medical Officer |
-- |
07/02/2025 |
| Mr. Jeffrey Cole |
Chief Operating Officer |
美元 363.72K |
31/07/2025 |
| Mr. Quang X. Pham |
Chairman of the Board and Chief Executive Officer |
美元 708.75K |
31/07/2025 |
|
|
| Dr. Lee Scott Golden, M.D. |
Director |
01/12/2025 |
| Dr. Glynn Wilson,PhD |
Independent Director |
31/07/2025 |
| Mr. Steven Zelenkofske |
Independent Director |
31/07/2025 |
| Mr. John Raymond Murphy |
Independent Director |
31/07/2025 |
| Mr. Quang X. Pham |
Chairman of the Board and Chief Executive Officer |
31/07/2025 |
|
|
|
|
